Skip to Main Content

Paper Details

Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
1
2023
BRAF, BRAF mutation, BRAF wild-type melanoma cells, BRAF-mutated cells, BRAF-mutated melanoma, Cancer, Metformin, Patients, Pembrolizumab, melanoma, metformin, patients, pembrolizumab, stage III, stage III melanoma, stage IIIA, IIIB, or IIIC
Author NameAffiliation
Georgina V LongMelanoma Institute Australia, the University of Sydney, and Mater and Royal North Shore Hospitals
Dirk SchadendorfUniversity Hospital Essen, Partner Site Essen & University Alliance Ruhr Research Center One Health
Caroline RobertGustave Roussy and Paris-Saclay University
  • 1 - 3

Datasets

Release 1.2